株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品リーダーシリーズ - 眼科用薬剤メーカー上位25社の分析 (2018〜2028年):網膜障害、アレルギー、炎症・感染症、緑内障、ドライアイ向け治療薬

Pharma Leader Series - Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs

発行 Visiongain Ltd 商品コード 294342
出版日 ページ情報 英文 223 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=139.96円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品リーダーシリーズ - 眼科用薬剤メーカー上位25社の分析 (2018〜2028年):網膜障害、アレルギー、炎症・感染症、緑内障、ドライアイ向け治療薬 Pharma Leader Series - Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs
出版日: 2018年07月19日 ページ情報: 英文 223 Pages
概要

世界の眼科用薬剤の市場規模は、2017年に230億米ドルに達しました。その内の39.1%を網膜障害向け製品が占めています。

当レポートでは、世界の点眼剤の市場について分析し、市場の全体的な構造や動向、主な市場促進・抑制要因、市場規模の動向見通し (今後10年間分)、製品種類別・疾患別・地域別の詳細動向、市場の求心力、世界各地の主要メーカー (全25社) および新興企業のプロファイル (収益額予測、治験の進行状況、SWOT分析) などの情報を取りまとめてお届けします。

第1章 レポート概要

第2章 点眼薬の概略

  • 製薬産業:概略
  • 世界規模での眼病の疾病負荷
  • 点眼薬:市場の内訳
  • 緑内障
    • 疾患の診断・治療方法
  • 加齢性黄斑変性症 (AMD)
  • 糖尿病性網膜症 (DR)
  • 眼アレルギーおよびアレルギー性結膜炎
  • 眼炎症性疾患
  • 眼の感染症
  • ドライアイ症候群
  • 治験のフェーズ (相)

第3章 世界の点眼薬市場

  • 世界の点眼薬市場の最新情勢
  • 売上高の予測 (今後11年間分)
  • 代表的な点眼薬
  • 点眼薬市場の代表的企業
    • 点眼薬メーカー上位25社
  • 点眼薬市場の内訳:売上高の予測 (今後11年間分)
    • 網膜障害向け点眼薬
    • 眼アレルギー・眼炎症性疾患・感染症向け点眼薬
    • 緑内障向け点眼薬
    • ドライアイ向け点眼薬
    • その他の点眼薬
  • 市場シェアの変化の見通し
  • 世界の点眼薬市場の促進・抑制要因
    • 市場促進要因
    • 市場抑制要因

第4章 米国の代表的な点眼剤メーカー

  • Allergan
    • 製品ポートフォリオ
    • 治験の最終段階にあるパイプライン製品
    • 市場収益額の予測 (今後11年間分)
    • SWOT分析
  • Pfizer
  • Regeneron
  • Akorn

第5章 欧州の代表的な点眼薬メーカー

  • Bayer
  • Novartis (Alconを含む)
  • Roche

第6章 アジア太平洋地域などの代表的な点眼薬メーカー

  • 参天製薬
  • 千寿製薬
  • Valeant

第7章 新興点眼薬メーカー

  • 小規模な製品ポートフォリオと有望なパイプライン候補薬を有する企業
  • Acucela
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics (AKB 9778)
  • Alimera Sciences (Iluvien、NADPH Oxidase阻害剤)
  • Amakem
  • Ampio Pharmaceuticals
  • Chengdu Kanghong Pharmaceutical
  • Eleven Biotherapeutics
  • EyeGate Pharmaceuticals
  • Gene Signal (Aganirsen)
  • Icon Bioscience
  • MacuCLEAR (MC 1101)
  • Neurotech
  • Omeros
  • OphthaliX (Can-Fite BioPharma)
  • Ophthotech (Fovista、Zimura)
  • 大塚製薬
  • pSivida Corp.
  • RXi Pharmaceuticals (ベバシラニブ)
  • Shire (Lifitegrast (SHP606)、Premiplex (SHP607))
  • ThromboGenics (Jetrea (ocriplasmin)、ThromboGgenics)

第8章 点眼薬市場の定性的分析

  • ポーターのファイブフォース分析:点眼薬市場の場合
    • 同一他社との競合:中
    • 新規参入企業の脅威:低
    • サプライヤーの交渉力:低
    • バイヤーの購買力:中
    • 代替製品の脅威:中

第9章 結論

  • 点眼薬:成長中のニッチ市場
  • 世界の点眼薬市場
    • 代表的な部門・製品・企業
  • 点眼薬市場の将来予測 (今後11年間分)
  • 点眼薬市場の将来像
    • 専業企業間での収益集中の傾向
    • ジェネリック医薬品の普及
    • 小企業が大きな影響を与える可能性
    • 点眼薬市場で勝ち抜く企業
  • 用語一覧
図表

List of Tables

  • Table 2.1: ICD 10 Classification of Visual Impairment, 2015
  • Table 2.2: Drug Treatments for Glaucoma, 2017
  • Table 2.3: Drug Treatments for AMD, 2017
  • Table 2.4: Drug Treatments for Ocular Allergy, 2017
  • Table 2.5: Drug Treatments for Ocular Inflammatory Disease, 2017
  • Table 2.6: Selected Drug Treatments for Eye Infections, 2017
  • Table 2.7: Clinical Trial Phases
  • Table 3.1: World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2017
  • Table 3.2: World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2028
  • Table 3.3: Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2017
  • Table 3.4: Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2017
  • Table 3.5: Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2017
  • Table 3.6: World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2017-2028
  • Table 3.7: Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028
  • Table 3.8: Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 3.9: Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 3.10: Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 3.11: Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028
  • Table 3.12: Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2017, 2023 and 2028
  • Table 4.1: Allergan: Overview, 2017
  • Table 4.2: Allergan: Ophthalmic Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 4.3: Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.4: Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.5: Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.6: Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.7: Allergan: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 4.8: Allergan: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 4.9: Pfizer: Overview, 2017
  • Table 4.10: Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.11: Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.12: Pfizer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 4.13: Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 4.14: Regeneron: Overview, 2017
  • Table 4.15: Regeneron: Eylea Revenue ($m), AGR (%) and CAGR (%) 2017-2028
  • Table 4.16: Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.17: Regeneron: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 4.18: Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 4.19: Akorn: Overview, 2017
  • Table 4.20: Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.21: Akorn: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 4.22: Akorn: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 5.1: Bayer: Overview, 2017
  • Table 5.2: Bayer: Eylea Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.3: Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.4: Bayer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 5.5: Novartis: Overview, 2017
  • Table 5.6: Novartis: Lucentis Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.7: Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.8: Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2017-2028
  • Table 5.9: Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2017-2028
  • Table 5.11: Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.12: Novartis: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 5.13: Novartis: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 5.14: Roche: Overview, 2017
  • Table 5.15: Roche: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2017-2028
  • Table 5.16: Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.17: Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.18: Roche: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 5.19: Roche: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 6.1: Santen: Overview, 2017
  • Table 6.2: Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2017
  • Table 6.3: Santen: Eylea Revenue ($m), AGR (%) and CAGR(%), 2017-2028
  • Table 6.4: Santen: Hyalein Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.5: Santen: Cosopt Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.6: Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.7: Santen: Diquas Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.8: Santen: Cravit Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.9: Santen: Alesion Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.10: Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.11: Santen: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 6.12: Santen: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 6.13: Senju: Overview, 2017
  • Table 6.14: Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2017
  • Table 6.15: Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.16: Senju: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 6.17: Senju: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 6.18: Valeant: Overview, 2017
  • Table 6.19: Valeant: Lotemax Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.20: Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.21: Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 6.22: Valeant: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 7.1: Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country
  • Table 9.1: Leading Ophthalmic Drugs Manufacturers: Revenues ($m), Market Share (%), 2018

List of Figures

  • Figure 1.1: Global Causes of Visual Impairment (% of cases), 2017
  • Figure 1.2: World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015 and 2026
  • Figure 1.3: Global Ophthalmic Drugs Market Segmentation Overview, 2017
  • Figure 2.1: Estimated Global Blindness and Visual Impairment (% of people), 2015
  • Figure 2.2: Estimated Global Prevalence of Visual Impairment (millions of people), 2015
  • Figure 2.3: Global Causes of Visual Impairment (% of cases), 2015
  • Figure 2.4: Global Causes of Blindness (% of cases), 2015
  • Figure 2.5: Classification of Glaucoma, 2017
  • Figure 3.1: World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2017
  • Figure 3.2: World Ophthalmic Drugs Market: Market Share (%) by Segment, 2017
  • Figure 3.3: World Ophthalmic Drugs Market Forecast: Revenue ($m) and AGR (%), 2018-2028
  • Figure 3.4: Top 9 Ophthalmic Drugs: Revenues ($m), 2017
  • Figure 3.5: Top 9 Ophthalmic Drugs: Market Share (%), 2017
  • Figure 3.6: Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenues ($m), 2017
  • Figure 3.7: Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2017
  • Figure 3.8: Retinal Disorders Drugs Market Forecast: Revenues ($m), 2017-2028
  • Figure 3.9: Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2017-2028
  • Figure 3.10: Glaucoma Drugs Market Forecast: Revenues ($m), 2017-2028
  • Figure 3.11: Dry Eye Drugs Market Forecast: Revenues ($m), 2017-2028
  • Figure 3.12: Other Ophthalmic Drugs Market Forecast: Revenues ($m), 2017-2028
  • Figure 3.13: World Ophthalmic Drugs Market: Market Share (%) by Segment, 2017
  • Figure 3.14: World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2023
  • Figure 3.15: World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2028
  • Figure 3.16: World Ophthalmic Drugs Market: Drivers and Restraints, 2018-2028
  • Figure 4.1: Allergan: Restasis Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.2: Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.3: Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.4: Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.5: Allergan: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 4.6: Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2017-2028
  • Figure 4.7: Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.8: Pfizer: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 4.9: Regeneron: Eylea Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.10: Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.11: Regeneron: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 4.12: Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.13: Akorn: Ophthalmic Drugs Market Share (%), 2017-2028
  • Figure 5.1: Bayer: Eylea Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.2: Bayer: Ophthalmic Drugs Revenue ($m) and AGR(%), 2017-2028
  • Figure 5.3: Bayer: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 5.4: Novartis: Lucentis Revenue ($m) and AGR(%), 2017-2028
  • Figure 5.5: Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.6: Novartis: Vigamox Revenue ($m) and AGR(%), 2017-2028
  • Figure 5.7: Novartis: Azopt Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.8: Novartis: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.9: Novartis: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 5.10: Roche: Lucentis Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.11: Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2017-2028
  • Figure 5.12: Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.13: Roche: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 6.1: Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2017
  • Figure 6.2: Santen: Major Prescription Ophthalmic Drugs, Revenue Share (%), FY 2017
  • Figure 6.3: Santen: Eylea Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.4: Santen: Hyalein Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.5: Santen: Cosopt Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.6: Santen: Tapros/Taflotan Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.7: Santen: Diquas Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.8: Santen: Cravit Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.9: Santen: Alesion Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.10: Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.11: Santen: Ophthalmic Drugs Market Share (%), 2017-2028
  • Figure 6.12: Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.13: Senju: Ophthalmic Drugs Market Share (%), 2017-2028
  • Figure 6.14: Valeant: Lotemax Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.15: Valeant: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.16: Valeant: Ophthalmic Drugs Market Share (%), 2017-2028
  • Figure 7.1: Gene Signal: Ophthalmic Drug Pipeline Progress
  • Figure 7.2: Ophthotech: Ophthalmic Drug Pipeline Progress
  • Figure 7.3: Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress
  • Figure 7.4: Shire: Ophthalmic Drug Pipeline Progress
  • Figure 8.1: Porter's Five Forces Analysis of the Ophthalmic Drugs Market, 2018-2028

COMPANIES LISTED

  • Abbott Laboratories (Abbott)
  • Abbvie
  • Actavis
  • Acucela
  • Advanced Vision Research (acquired by Akorn)
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics
  • Akorn Pharmaceuticals
  • Alcon (subsidiary of Novartis)
  • Alimera Sciences
  • Allergan
  • Allegro Ophthalmics
  • Altheos
  • Amakem
  • Ampio Pharma
  • Asahi Glass
  • AstraZeneca
  • Aton Pharma (acquired by Valeant)
  • Banyu Pharmaceutical (part of Merck)
  • Bausch and Lomb (subsidiary of Valeant)
  • Bayer
  • Bayer Yakuhin (Japanese subsidiary of Bayer)
  • BioDiem
  • Bicycle Therapeutics
  • Biogen Idec
  • BioInvent International
  • Biovail Corporation (part of Valeant)
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Chengdu Kanghong Pharmaceutical
  • Chiron Corportation (part of Novartis)
  • Chugai Pharmaceutical (part of Roche)
  • CIBA VISION (part of Novartis)
  • Ciba-Geigy (part of Novartis)
  • Colby Pharmaceutical Company (Colby)
  • CoMentis
  • Daiichi Sankyo
  • Eleven Biotherapeutics
  • Eli Lilly and Company (Lilly)
  • EyeGate Pharmaceuticals
  • Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
  • Fougera Pharmaceuticals (acquired by Novartis)
  • Gene Signal
  • Genentech (subsidiary of Roche)
  • Genzyme (subsidiary of Sanofi)
  • Gilead Sciences
  • GSK
  • ICN Pharmaceuticals (original Valeant company)
  • Icon Bioscience
  • Inamed Corporation (subsidiary of Allergan)
  • Inception Sciences, Inc.
  • InSite Vision
  • Inspire Pharmaceuticals (acquired by Merck)
  • ISTA Pharmaceuticals (part of Valeant)
  • Jerini AG
  • Jerini Ophthalmic (part of Jerini AG)
  • Johnson & Johnson
  • Kestrel Ophthalmics
  • Kyorin Pharmaceutical
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Lpath
  • MacuCLEAR
  • MacuSIGHT, Inc.
  • MAP Pharmaceuticals (acquired by Allergan)
  • Meda
  • Medicis Corporation (acquired by Valeant)
  • Merck & Co. (Merck)
  • MerLion Pharmaceuticals
  • MSD K.K. (part of Merck)
  • Mylan Pharmaceuticals
  • Mystic Pharmaceuticals
  • Neurotech
  • NicOx
  • Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
  • NovaBay Pharmaceuticals
  • Novagali Pharma (acquired by Santen)
  • Novartis
  • Novo (subsidiary of Novo Nordisk)
  • Novo Nordisk
  • Oakwood Laboratories
  • OcuSciences
  • Omeros
  • Onyx Pharmaceuticals
  • OphthaliX (part-owned by Can-Fite BioPharma)
  • Ophthotech
  • OPKO Health
  • Ora
  • OSI Pharmaceuticals
  • Othera Pharmaceuticals (acquired by Colby)
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • OXiGENE
  • Parke-Davis (subsidiary of Pfizer)
  • PDL BioPharma
  • Pfizer
  • Pharmacia (acquired by Pfizer)
  • Potentia Pharmaceuticals
  • Premacure
  • Procter & Gamble
  • pSivida
  • Quark Pharmaceuticals
  • Reckitt Benckiser
  • Regeneron
  • RetroSense Therapeutics
  • ReVision Therapeutics
  • Roche
  • RXi Pharmaceuticals
  • Sandoz (part of Novartis)
  • Sanofi
  • Santen Pharmaceutical Co. (Santen)
  • SARcode Bioscience
  • Schering-Plough (part of Merck)
  • Senju
  • Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)
  • Senju USA Inc. (subsidiary of Senju)
  • Shire
  • Sirion Therapeutics
  • Sirna Therapeutics
  • Sirnaomics
  • SkinMedica (subsidiary of Allergan)
  • Spark Therapeutics
  • Symphony ViDA
  • Takeda Pharmaceutical
  • Teva
  • The Patent Board
  • ThromboGenics
  • Upjohn (acquired by Pfizer through Pharmacia)
  • Valeant Pharmaceuticals
  • Ventana Medical Systems (acquired by Roche)
  • Versant Ventures
  • Warburg Pincus LLC
  • Warner-Lambert (acquired by Pfizer)
  • Watson Pharmaceuticals
  • Wyeth Pharmaceuticals (part of Pfizer)

List of Other Organizations Mentioned in the Report:

  • A*STAR Institute for Infocomm Research (Singapore)
  • American Academy of Ophthalmology (AAO)
  • American Diabetes Association
  • American Society of Retina Specialists (ASRS)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • Council of Europe
  • Emory University
  • European Medicines Agency (EMA)
  • Foundation Fighting Blindness (FFB) (US)
  • Health Canada
  • Institute of Experimental Medicine (Russia)
  • Institute of Ocular Pharmacology, Texas A&M (US)
  • Institute of Ophthalmology, University College London (UK)
  • Intellectual Property Appellate Board (India)
  • International Diabetes Federation
  • Internet Archive
  • Japan Patent Office (JPO)
  • Mayo Clinic
  • Ministry of Health, Labour and Welfare (MHLW) (Japan)
  • Monash University
  • National Eye Institute (NEI) (US)
  • National Health Service (NHS) (UK)
  • National Institute for Health and Care Excellence (NICE) (UK)
  • NHS Scotland
  • Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)
  • Novartis Venture Funds (NVF) (part of Novartis)
  • Ophthalmology External Research Unit (part of Pfizer)
  • Ophthrisi (GSK research unit)
  • Rinat (Pfizer research unit)
  • Texas Emerging Technology Fund
  • Therapeutic Goods Administration (TGA) (Australia)
  • Tokyo University of Science
  • United States Food and Drug Administration (FDA)
  • University of Florida
  • University of Kentucky
  • University of Melbourne
  • University of Michigan
  • US Preventive Services Task Force (USPSTF)
  • US Securities and Exchange Commission (SEC)
  • World Health Organization (WHO)
目次
Product Code: PHA0324

The global ophthalmic drugs market was valued at $23bn in 2017. The market was dominated by the Retinal Disorder drug submarket which held 39.1% of the global ophthalmic drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 223-page report you will receive 83 tables and 71 figures- all unavailable elsewhere.

The 223-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global ophthalmic drugs market revenue forecasts from 2018-2028

Global ophthalmic drugs market revenue orecasts from 2018-2028, by submarket:

  • Retinal Disorder Drugs
  • Allergic, Inflammatory & Infective Drugs
  • Glaucoma Drugs
  • Dry Eye Drugs
  • Other Ophthalmic Drugs

Revenue forecasts from 2018-2028 of the leading ophthalmic drugs:

  • Alphagan
  • Avastin
  • Azopt
  • Eylea
  • Lucentis
  • Lumigan & Ganfort
  • Other Ophthalmic Drugs
  • Restasis
  • Vigamix
  • Xalatan/Xalacom

Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:

  • Acucela
  • Akorn
  • Alimera Sciences
  • Allergan
  • Amakem
  • Bayer
  • Chengdu Kanghong
  • EyeGate Pharmaceuticals
  • Gene Signal
  • Icon Biosciences
  • MacuCLEAR
  • Neurotech
  • Novartis
  • Omeros
  • Ophthotech
  • Otsuka Pharmaceutical
  • Pfizer
  • pSivida Corp.
  • Regeneron
  • Roche
  • Santen
  • Senju
  • Shire
  • ThromboGenics
  • Valeant

Our report provides an overview, revenue forecast from 2018-2028 of the ophthalmic drugs segment, revenue forecast from 2018-2028 of the leading drugs, product pipeline and SWOT Analysis, for these companies:

  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • Bayer
  • Novartis
  • Pfizer
  • Regeneron
  • Roche
  • Santen
  • Senju
  • Valeant

Our report provides these Qualitative Analysis:

  • Drivers and Restraints of the Global Ophthalmic Drugs market
  • SWOT Analysis of selected leading companies
  • Porter's Five Forces Analysis of the Global Ophthalmic Drugs Market

Visiongain's study is intended for anyone requiring commercial analyses for the ophthalmic drugs market. You find data, trends and predictions.

Buy our report today ‘Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Ophthalmic Drugs Market Overview
  • 1.2. Global Ophthalmic Drugs Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Ophthalmic Drugs

  • 2.1. The Pharmaceutical Industry: Very Brief Overview
  • 2.2. The Global Burden of Eye Disease
  • 2.3. Ophthalmic Drugs: Market Segmentation
  • 2.4. Glaucoma: the ‘Silent Thief of Sight'
    • 2.4.1. A Classification of Glaucoma
    • 2.4.2. Risk Factors for Glaucoma
    • 2.4.3. Diagnosis of Glaucoma
    • 2.4.4. Drug Treatment of Glaucoma
    • 2.4.5. Laser Treatment and Surgery for Glaucoma
  • 2.5. Age-Related Macular Degeneration (AMD)
    • 2.5.1. Dry (Non-Exudative) AMD
    • 2.5.2. Wet (Exudative) AMD
    • 2.5.3. Risk Factors for AMD
    • 2.5.4. Diagnosis of AMD
    • 2.5.5. Treatment of AMD
  • 2.6. Diabetic Retinopathy (DR)
    • 2.6.1. Diagnosis of Diabetic Retinopathy
    • 2.6.2. Treatment of Diabetic Retinopathy
  • 2.7. Ocular Allergy and Allergic Conjunctivitis
    • 2.7.1. Diagnosis of Ocular Allergy
    • 2.7.2. Treatment of Ocular Allergy
  • 2.8. Ocular Inflammatory Disease
    • 2.8.1. Treatment of Ocular Inflammatory Disease
  • 2.9. Eye Infections
    • 2.9.1. Treatment of Eye Infections
  • 2.10. Dry Eye Syndrome
    • 2.10.1. Treatment of Dry Eye Syndrome
  • 2.11. Phases of Clinical Trials

3. Ophthalmic Drugs: World Market 2018-2028

  • 3.1. The World Ophthalmic Drugs Market in 2018
  • 3.2. World Ophthalmic Drugs Market: Sales Forecast 2018-2028
  • 3.3. Leading Ophthalmic Drugs
  • 3.4. Leading Companies in the Ophthalmic Drugs Market
    • 3.4.1. Top 25 Ophthalmic Drug Manufacturers
  • 3.5. Ophthalmic Drugs Market Segments: Sales Forecasts 2018-2028
    • 3.5.1. Retinal Disorders Drugs Market: Sales Forecast 2018-2028
    • 3.5.2. Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2018-2028
    • 3.5.3. Glaucoma Drugs Market: Sales Forecast 2018-2028
    • 3.5.4. Dry Eye Drugs Market: Sales Forecast 2018-2028
    • 3.5.5. Other Ophthalmic Drugs Market: Sales Forecast 2018-2028
  • 3.6. How Will Market Shares Change to 2028?
  • 3.7. World Ophthalmic Drugs Market: Drivers and Restraints 2018-2028
    • 3.7.1. World Ophthalmic Drugs Market: Analysis of Drivers
    • 3.7.2. World Ophthalmic Drugs Market: Analysis of Restraints

4. Leading US Ophthalmic Drug Manufacturers 2018-2028

  • 4.1. Allergan Overview
    • 4.1.1. Allergan: Ophthalmic Product Portfolio
    • 4.1.2. Allergan: Late Stage Ophthalmic Product Pipeline
    • 4.1.3. Allergan: Ophthalmic Revenue Forecast 2018-2028
    • 4.1.4. Allergan: SWOT Analysis
  • 4.2. Pfizer Overview
    • 4.2.1. Pfizer: Ophthalmic Product Portfolio
    • 4.2.2. Pfizer: Ophthalmic Product Pipeline
    • 4.2.3. Pfizer: Revenue Forecast 2018-2028
    • 4.2.4. Pfizer: SWOT Analysis
  • 4.3. Regeneron Overview
    • 4.3.1. Regeneron: Ophthalmic Product Portfolio
    • 4.3.2. Regeneron: Ophthalmic Product Pipeline
    • 4.3.3. Regeneron: Revenue Forecast 2018-2028
    • 4.3.4. FDA Approves Zaltrap (aflibercept)
    • 4.3.5. Eylea/Zaltrap and the Davis-Smyth Patent Agreements
    • 4.3.6. Regeneron: SWOT Analysis
  • 4.4. Akorn Overview
    • 4.4.1. Akorn: Ophthalmic Product Portfolio
    • 4.4.2. Akorn: Revenue Forecast 2018-2028
    • 4.4.3. Akorn: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers 2018-2028

  • 5.1. Bayer Overview
    • 5.1.1. Bayer: Ophthalmic Product Pipeline
    • 5.1.2. Eylea: non-US Sales Forecast 2018-2028
    • 5.1.3. Bayer: Revenue Forecast 2018-2028
  • 5.2. Novartis (including Alcon) Overview
    • 5.2.1. Novartis: Ophthalmic Product Portfolio
    • 5.2.2. Novartis: Ophthalmic Product Pipeline
    • 5.2.3. Novartis: Revenue Forecast 2018-2028
    • 5.2.4. Novartis: SWOT Analysis
  • 5.3. Roche Overview
    • 5.3.1. Roche: Ophthalmic Product Portfolio
    • 5.3.2. Roche: Ophthalmic Product Pipeline
    • 5.3.3. Roche: Revenue Forecast 2018-2028
    • 5.3.4. Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2018-2028

  • 6.1. Santen Overview
    • 6.1.1. Santen: Ophthalmic Product Portfolio
    • 6.1.2. Santen: Ophthalmic Product Pipeline
    • 6.1.3. Santen: Revenue Forecast 2018-2028
    • 6.1.4. Santen: SWOT Analysis
  • 6.2. Senju Overview
    • 6.2.1. Senju: Ophthalmic Product Portfolio
    • 6.2.2. Senju: Ophthalmic Product Pipeline
    • 6.2.3. Senju: Revenue Forecast 2018-2028
    • 6.2.4. Senju: SWOT Analysis
  • 6.3. Valeant Overview
    • 6.3.1. Valeant: Ophthalmic Product Portfolio
    • 6.3.2. Valeant: Ophthalmic Product Pipeline
    • 6.3.3. Valeant: Revenue Forecast 2018-2028
    • 6.3.4. Valeant: SWOT Analysis

7. Emerging Ophthalmic Drug Manufacturers in 2017

  • 7.1. Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2017
  • 7.2. Acucela
  • 7.3. Aerie Pharmaceuticals
  • 7.4. Aerpio Therapeutics: Developing AKB 9778
  • 7.5. Alimera Sciences
  • 7.5.1. Iluvien: Increasing Geographical Reach and Increasing Sales
  • 7.5.2. NADPH Oxidase Inhibitors Offer Potential for Dry AMD
  • 7.6. Amakem
  • 7.7. Ampio Pharmaceuticals
  • 7.8. Chengdu Kanghong Pharmaceutical
  • 7.9. Eleven Biotherapeutics
  • 7.10. EyeGate Pharmaceuticals
  • 7.11. Gene Signal
    • 7.11.1. Aganirsen: Preventing Corneal Graft Rejection
  • 7.12. Icon Bioscience
  • 7.13. MacuCLEAR
    • 7.13.1. MC 1101: a Potential Therapy for Dry AMD
  • 7.14. Neurotech
  • 7.15. Omeros
  • 7.16. OphthaliX (Can-Fite BioPharma)
  • 7.17. Ophthotech
    • 7.17.1. Fovista: Potential Game-Changer in AMD
    • 7.17.2. Fovista: Significant Improvement on Lucentis in Phase II Trials
    • 7.17.3. Zimura: Complement C5 Inhibitor
  • 7.18. Otsuka Pharmaceutical
  • 7.19. pSivida Corp.
  • 7.20. RXi Pharmaceuticals: Will Bevasiranib Resume Development?
  • 7.21. Shire
    • 7.21.1. Lifitegrast (SHP606) for Dry Eye
    • 7.21.2. Premiplex (SHP607): Preventing Retinopathy of Prematurity
  • 7.22. ThromboGenics
    • 7.22.1. Jetrea (ocriplasmin)
    • 7.22.2. ThromboGgenics: Leading Diabetic Eye Disease Pipeline

8. Qualitative Analysis of the Ophthalmic Drugs Market 2018-2028

  • 8.1. Porter's Five Forces Analysis of the Ophthalmic Drugs Market
    • 8.1.1. Rivalry Among Competitors [Medium]
    • 8.1.2. Threat of New Entrants [Low]
    • 8.1.3. Power of Suppliers [Low]
    • 8.1.4. Power of Buyers [Medium]
    • 8.1.5. Threat of Substitutes [Medium]

9. Conclusions

  • 9.1. Ophthalmic Pharmaceuticals: A Growing Niche Market
  • 9.2. The World Ophthalmic Drugs Market in 2017
    • 9.2.1. Leading Ophthalmic Drugs Market Segments
    • 9.2.2. Leading Ophthalmic Drugs
    • 9.2.3. Leading Ophthalmic Drugs Companies
  • 9.3. World Ophthalmic Drugs Market Forecast 2018-2028
  • 9.4. The Future of the Ophthalmic Drugs Market?
    • 9.4.1. Increasing Revenue Concentration among Specialist Companies
    • 9.4.2. The Rise of Generics
    • 9.4.3. Small Companies Can Have a Big Impact
    • 9.4.4. What Will Succeed in the Ophthalmic Drugs Market?
  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form
Back to Top